Advisory board · Dr. Hiroshi Abbott

18 Jan 2026 · In person · Dr. Hiroshi Abbott, Royal Marsden · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0037—

Capture insight from this engagement

Location: Royal Marsden
Therapeutic area: Oncology
Country: United Kingdom
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

PD-L1 testing turnaround
Chemotherapy-free first line
Elderly / ECOG 2 patients

Scientific content used

VOYAGE-1 pivotal data summary

Questions raised

How should grade 2 infusion reactions be managed without steroids?
What is the evidence for re-challenge with checkpoint inhibitors after progression on vantrelimab?

Notes

Advisory board with radiation oncologist at Royal Marsden. Discussed pd-l1 testing turnaround, chemotherapy-free first line, elderly / ecog 2 patients.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 5
Depth of exchange: 3
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0037

Audit history (1)

All create, update and approval events for this record

Time	Action	User	Field	Change	Reason	Source
11 Sept 2026, 12:06 UTC	Close	GNGrace Nakamura	dueDate	Planned → Reviewed	—	Integration